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THE induction of tumours by carcinogenic polycyclic hydrocarbons, amongst
other compounds, can be inhibited to some extent by substances which stimulate
their metabolic inactivation. This phenomenon has been recently reviewed by
Wattenberg (1966), who refers to it as chemoprophylaxis, and by Gelboin (1967).
The ability of aromatic compounds to reduce mammary tumour induction by
7, 12-dimethylbenz(a)anthracene (DMBA) was reported by Huggins, Grand and
Fukunishi (1966). Wattenberg and Leong (1965), having shown that pheno-
thiazines stimulate enzymic hydroxylation of polycyclic hydrocarbons, later
demonstrated that pretreatment of rats with these compounds reduced the
ability of DMBA to induce mammary tumours (Wattenberg and Leong, 1967).
One of the most potent stimulators of drug metabolism, and, in particular of
the metabolism ofDMBA, is 3-methylcholanthrene (3-MC) (HugginsandFukunishi,
1964; Dao and Varela, 1966; see Gelboin, 1967, for an extensive review of the
literature). This substance increases the rate at which the liver can metabolize
DMBA to more polar, hydroxylated derivatives (Boyland and Sims, 1967; Jellinck
and Goudy, 1967; Levin and Conney, 1967). Since hydroxylated metabolites
of DMBA have proved to be weakly carcinogenic or non-carcinogenic in rat
mammary tissue (Boyland, Sims and Huggins, 1965; Wheatley and Inglis, 1968),
the parent compound itselfis probably responsible for mammary tumourinduction.
In this paper a comparison is made between mammary tumour induction by
DMBA in rats pretreated with 3-MC (to stimulate the metabolism of polycyclic
hydrocarbons) and in rats pretreated with SKF 525-A (fl-diethylaminoethyl-
diphenyl-n-propyl acetate) which is a potent inhibitor of drug metabolism (Cook,
Toner and Fellows, 1954; Rogers and Fouts, 1964). It has recently been shown
that SKF 525-A can inhibit the metabolism of DMBA and prevent the formation
of an adrenocorticolytic derivative in the liver (Wheatley, 1968). If 3-IMC can
reduce the carcinogenic action of DMBA by stimulating its removal, it was
considered that SKF 525-A might potentiate the carcinogenicity of IDMBA by
preventing its metabolism to inactive derivatives.
MATERIALS AND METHODS
Sprague-IDawley female rats were obtained commercially from an accredited
stock (Oxford Laboratory Animal Colonies, Bicester, Oxon) at 40 ± 1 days of age.
They were housed 5 rats per cage in metal cages, fed modified Thompson rat
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cube containing 14% skimmed milk (North-Eastern Agricultural Co-operative
Society Ltd., Aberdeen) and allowed water ad libitum. The ambient temperature
was 22 ± 1° C. and the rats had normal daylight hours.
EXPERIMENT 1. PretreatmentofRats with 3-MCandSKF 525-A at Intervals which
Protect Against the Systemic and Adrenocorticolytic Effects of DMBA
Experimental groUps. At 49 days of age the rats were randomized into 8
groups of 20 rats. Three of the groups received on this day 04 ml. of a 15%
cotton-seed oil emulsion containing 1 mg. 3-methylcholanthrene (3-MC) intra-
peritoneally 24 hr. before DMBA. This gives a high degree of protection against
DMBA-induced adrenal necrosis (Huggins and Fukunishi, 1964).
At 50 days of age, 3 further groups were injected intraperitoneally with 10 mg./
kg. body weight /3-diethylaminoethyldiphenyl-n-propyl acetate (SKF 525-A; Smith,
Kline and French, Ltd., Welwyn Garden City, Hertfordshire) in 1 ml. sterile
saline 1 hr. before DMBA. This treatment has also proved highly effective against
DIMBA-induced adrenal necrosis (Wheatley, 1968).
The 2 renmaining groups of rats were injected intraperitoneally with 1 ml.
sterile saline 1 hr. before DMBA as controls (see Table I).
7,12-Dirnethylbenz(a)anthracene (IDMBA) was given intravenously in 15%
cotton-seed oil emulsion containing 5 mg./ml. Groups of rats pretreated with
3-I'IC or SKF 525-A received 2-5, 5 0 or 15 0 mg. IDMBA in a single injection.
Control groups received 2-5 or 5-0 mg. DMBA, the 15-0 mg. dose not being used
since this is lethal within 48 hr. for unprotected rats. The intravenous route of
IDMBA administration was chosen in preference to intragastric instillation because
it excludes the possibility that pretreatments affect the passage of the carcinogen
across the mucosal barrier.
Deaths within the first 72 hr. after treatment were far more numerous than
anticipated in the control group receiving 5*0 mg. DMBA. To offset the loss of
rats from this group, a further 74 rats from the same stock were injected.
Tumnour methods. Surviving rats were palpated each week from the fourth
week after DMBA for mammary tumours. Tumours were measured once a week
by the method of Stevens, Stevens and Currie (1965). Ifspontaneous regression
was detected from the growth curves of a tumour, a biopsy was perfornmed to
obtain histological evidence of the nature of the lesion. Rats surviving 4 months
or more after DMBA treatment were included in the analysis of results. At the
end of a 6 month observation period, all the surviving rats were killed and
examined thoroughly for tumours. Tumours and suspected tumours were excised
aind fixed in 4% neutral buffered formaldehyde. Paraffin sections (5 ,u) were
stained with haematoxylin and eosin.
EXPERIMENT 2.- Nron-,protectivePretreatment ofRats with 3-MCantdSKF 525-A
In design, experiment 2 was basically the same as experiment 1 except that
pretreatments ofrats with 3-MC and SKF 525-A weregiven at times which afforded
no protection against the systemic or adrenocortical toxicity of DMBA and there-
fore the 15 mg. DMBA dose could not be used.
3-MC given I hr. before DMBA affords no protection against adrenal necrosis
(Huggins and I ukunishi, 1964) since insufficient time elapses for the induction of
mnicrosomal detoxification enzyme systems. Two of the 6 groups of rats in this
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experiment therefore received 1 mg. 3-MC intraperitoneally 1 hr. before 2%5 my.
or 5 0 my. DMBA intravenously. Since the inhibitory action of SKF 525-A on
drug metabolism is lost within 24 hr. of treatment (Rogers and Fouts, 1964;
Wheatley, 1968), 2 further groups of rats received 10 mg./lky. SKF 525-A intra-
peritoneally 24 hr. before 2-5 mg. or 50 my. DMBA intravenously. The remaining
2 groups ofrats were given 1.0 ml. saline 24 hr. before 2-5 mg. or 560 mg. DMBA.
Sufficient rats were dosed in each group to allow survival ofabout 20 rats over the
6 month observation period for tumours (see Table II). Other methods were the
same asinexperiment 1.
RESULTS
EXPERIMENT 1.-Effect of Protective Pretreatments with 3-MC and SKF 525-A on
the Induction of Mammary Tumours by DMBA
Survival ofrats in the 6 months following DMBA treatment is shown in Fig. 1.
In the control groups, systemic toxicity combined with adrenal damage led to a
mortality of over 25% after 2 5 mg. DMBA and 80% after 5-0 mg. DMBA.
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FIG. 1. Survival curves of rats in Experiment 1.
0... 0 3-MC 1 mg. i.p. 1 hr. before DMBA 25 mg. i.v.
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Fewer deaths occurred in protected rats given these doses of DMBA but in the
groups of rats injected with 15 mg. DMBA deaths were frequent within the first
month ofthe experiment.
3-Methylcholanthrene pretreatment compared with controls.-3-MC pretreated
rats given 2-5 mg. DMBA developed no mammary lesions (see TableI). Compared
with controls receiving 2-5 mg. DMBA, the difference is significant (P < 0 05).
After 5 mg. DMBA, fewer 3-MC pretreated rats developed tumours than controls
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but in this case the difference was not statistically significant. Rats given
15 mg. DMBA after 3-MC pretreatment showed a higher incidence of mammary
tumours than pretreated rats given 5 mg. DMBA.
SKF 525-A pretreatment compared with controls
A highly significant increase in the percentage of rats developing tumours
after 2-5 my. DMBA was seen in rats pretreated with SKF 525-A by comparison
with controls (P < 0.005). The difference between the groups is further empha-
sized by the fact that SKF 525-A-pretreated rats developed about 9 times as
many mammary lesions as controls (P < 0.0005) and 6 times as many adeno-
carcinomas (P < 0.001) (see Table I).
There was a higher incidence of SKF 525-A pretreated rats developing
mammary tumours after 5 my. DMBA compared with controls, but the difference
was not significant (P < 0.2). Although the total tumour yield was higher, the
average number of mammary lesions per tumour-bearing rat was in fact slightly
smaller than the control figure. Compared with SKF 525-A-pretreated rats
given 2-5 mg. DMBA, neither the incidence ofSKF 525-A-pretreated rats develop-
ing tuimours after 5 mg. DMBA nor the total tumour yield was significantly higher.
By the end ofthe observation period, the numbers ofthe SKF525-A-pretreated
rats which had received 15mg. DMBA were considerably depleted. Nevertheless,
of the 9 rats surviving for 4 months or more, only 4 developed tumours. Three
of these 4 rats produced a total of 7 adenocarcinomas and 4 fibroadenomas, but
the high total tumour yield in this small group (Table I) was dueto 1 ratdeveloping
19 adenocarcinomas, many of which arose between 9 and 14 weeks after DMBA
treatment.
Comparisons oftumour induction in 3-MCpretreated, SKF 525-A-pretreated and
control rats. Fig. 2-5 compare the effects of stimulated and inhibited metabolism
of DMBA on mammary tumour induction. In Fig. 2, a comparison is made
between the groups receiving 2-5 mg. DMBA. It shows the marked significant
difference at this near critical dose level of DMBA between the effects ofenhanced
metabolism by 3-MC pretreatment and inhibited metabolism by SKF 525-A
pretreatment (P < 0*0005 between these two groups). In Fig. 3, the comparison
is drawn for 5 mg. DMBA. Again the curves fall into the same relationship
SKF 525-A increasing the incidence of rats developing mammary tumours and
3-MC decreasing the incidence compared with the controls. Neither of these
differences is significant and furthermore, the difference between the incidence
of tumour-bearing rats in 3-MC-pretreated and SKF 525-A-pretreated groups is
not quite significant at the 5% level (P < 0 1 > 0.05). However, there was a
significantly greater tumour yield in the SKF 525-A-pretreated rats compared
with 3-MC-pretreated rats (P < 0.05). F"ig. 4 shows that in the SKF 525-A-
pretreated rats the 2 lower dose levels induced tumours in about the same percen-
tage of rats whereas 15 mg. DMBA was less effective. Fig. 5 compares tumour
induction in 3-MC-pretreated rats at the 3 different dose levels of DMBA. The
inhibitory action of 3-MC-pretreatment on tumour induction at the 2-5 mg.
IDMBA dose level is overcome by increasing the dose of carcinogen.
Table I also summarizes further details of tumours arising in the 8 different
groups of rats. The distinguishing histological features of the different types of
tumours are shown in Fig. 6-9. No large differences were found in the mean
detection time oftumours between the various groups. The analysis ofmammary
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FIG. 2. Comparison of the incidence of rats developing mammary tumouirs over 6 months in
3-MC-pretreated, SKF 5-215-A-pretreated and control rats given 2-5 mg. DMBA i.v.
FIG. 3.- Comparison as for Fig. 2 but for 5 mg. DMBA i.v.
FIG. 4. Comparison between SKF 525-A-pretreated rats given 2- 5, 5 0 and 15 mg. DMBA i.v.
FiG. 5. Comparison between 3-MC-pretreated rats given 2 5, 5 0 and 15 mg. DMBA i.v.
......... DMBA 2-5 mg.i.v.
- - -- ,, 5-0mg. i.v.
,, 15-0 mg. i.v.
O 3-MC 1 mg. i.p., 24 hr. pretreatment.
SKF 525-A 10 mg./kg. i.p., 1 hr. pretreatment.
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adenocarcinomas according to their growth behaviour shows no outstanding
differences but points to a preponderance of static tumours in most groups.
The number of fibromas which arose during the course of the experiment is
also included in Table I. It is noteworthy that these lesions were found in close
association with the mammary pads. They appear earlier and with greater
frequency in DMBA-treated rats than in untreated rats, suggesting that they
develop in response to DMBA.
Several lesions other than those of the mammary tissues were found during the
experiment. One rat given 3-MC-pretreatment before 5 0 mg. DMBA developed
a reticulosis, tentatively identified as a lymphoblastic leukaemia; another receiving
the same pretreatment before 15 0 mg. DMBA also developed a reticulosis which
appeared histologically consistent with a lymphocytic leukaemia. In the 5-0
mg. DMBA control group, a kidney lesion was found at necropsy in 1 rat
tentatively identified as a fibrosarcoma.
EXPERIMENT 2.-Effect on Non-protective Pretreatments with 3-MC and SKF 525-A
on the Induction of Mammary Tumours by DMBA
The repeat of Experiment 1 in which rats received non-protective pretreat-
ments with 3-MC and SKF 525-A at 1 hr. and 24 hr. before DMBA respectively
resulted in a high mortality in all 3 groups of rats receiving 5 mg. DMBA intra-
venously. No significant differences in the percentage of rats developing
mammary tumours were found between the groups of rats given 2-5 mg. LMBA,
or between the groups given 5.0 mg. DMBA (Table II, and Fig. 10 and 11).
There were no significant differences in tumour yield or in the latent period of
tumour detection between the groups given 2-5 mg. DMBA, or between the groups
given 5.0 mg. DMBA.
In this experiment, several tumours not associated with mammary tissue
arose. In a rat given 3-MC before 2-5 DMBA, a reticulosis developed which
appeared histologically similar to a lymphoblastic leukaemia. In the group
given SKF 525-A before 5 mg. DMBA one rat developed an ear-duct tumour;
a second rat developed a squamous carcinoma of the skin and a uterine polyp,
the latter probably being a malignant tumour of smooth muscle origin.
DISCUSSION
The Huggins method of producing tumours in rats (Huggins, Grand and Bril-
lantes, 1961; Huggins, Morii and Grand, 1961) has proved useful for studying the
effects of interference with the metabolism of DMBA on tumour induction. The
administration of the carcinogen as a single dose obviates the difficulties encoun-
tered in attempting to influence the rate ofmetabolism ofcarcinogens whichrequire
chronic administration, as in previous experiments of, for example, Richardsoni,
EXPLANATION OF PLATE.
Frc:. 6-9. Examples of the tumours arising in the mammary glands of Sprague-Dawley rats in
response to DMBA, representative of the histological classifications in Tables I and II.
Fig. 6.-Fibroma. Haematoxylin and eosin. x 290.
Fig. 7.-Fibroadenoma. H. & E. x 230.
Fig. 8. Adenoma. H. & E. x 230.
Fig. 9. Adenocarcinoma, ani example showing the cellularity of the mammary epithelium in a
growing tumour. AMany mitotic figures can be seen. H. & E. x 165.
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Stein and Borsos-Nachtnebel (1952), Meechan, McCafferty and Jones (1953) and
Miller, Miller, Brown and MacDonald (1958). Furthermore, by choosing the
intravenous route of administration of DMBA (Huggins, Morii and Grand, 1961)
in preference to the intragastric route in the present experiments, rats were
exposed systemically and immediately to known amounts ofDMBA at accurately
selected times after pretreatment, thereby eliminating possible effects ofpretreat-
ment drugs on absorption and metabolism of DMBA by the gut mucosa. The
influence of such factors cannot be excluded from the experiments of Dao (1964)
and Wattenberg and Leong (1967).
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FIG. 1O.-Comparison of the incidence of rats developing mammary tumours over 6 months
in 3-MC, SKF 525-A and control rats given 2-5 mg. DMBA i.v. In this case the 3-MC and
SKF 525-A pretreatment times were given at non-protective times.
FIG. 11.-Comparison as for Fig. 10 but for 5 mg. DMBA i.v.
......... DMBA 2
-5 mg. i.v.
- -- -- - 9,, 5-0mg. i.v.
o 3-MC 1 mg. i.p., 1 hr. pretreatment.
* SKF 525-A 10 mg./kg. i.p. 24 hr. pretreatment.
The most interesting outcome of the experiments is the degree to which
stimulation and inhibition of the metabolism of DMBA can influence mammary
tumour induction by a near-critical dose level (2.5 mg.) of the carcinogen. (The
rats used in this study appear considerably less sensitive to mammary tumour
induction than those used by Huggins, Morii and Grand (1961) who found that
2-5 mg. DMBA intravenously induced tumours in every rat.) In contrast to the
results with 2.5 mg. DMBA, the less significant differences between the groups
given 5-0 mg. DMBA demonstrate that, with higher dose levels of carcinogen, it
becomes increasingly more difficult to affect tumour induction by stimulating
or inhibiting the metabolism of the carcinogen (cf. Wattenberg and Leong, 1967).
The evidence from the transplantation experiments of Dao, Tanaka and Gawlak
69
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(1964) indicates that mammary tumour initiation is a rapid process which can
occur within 4 hr. of DMBA administration. It is not surprising, therefore, that
stimulation of the metabolic inactivation of DMBA will be ineffective as a chemo-
prophylactic measure against DMBA when the carcinogen is administered in
doses well above the critical level for tumour induction.
Whilst 3-MC given 24 hr. before DMBA inhibits mammary tumour induction
by 2-5 mg. DMBA, the observation that a pretreatment given only 1 hr. before
DMVIBA does not influence mammary tumour induction indicates that sufficient
time must elapse for enzyme stimulation to occur in the liver before protection
against mammary tumour induction can be achieved. It also demonstrates that
the prophylactic effect of 3-MC cannot be due to competition for sites of action
in the mammary epithelium.
SKF 525-A is known to exert a marked inhibitory action on hepatic micro-
somal enzyme systems (" drug-metabolizing enzymes ") which are dependent
upon NADH and 02 (Cooper and Brodie, 1955). The metabolism of DMBA to
an adrenal-damaging derivative in these sites is inhibited by SKF 525-A for a
period of about 12 hr. but not for 24 hr. (Wheatley, 1968). It is seen from the
present experiments that SKF 525-A strikingly enhances tumour induction when
given 1 hr. before 2x5 mg. DMBA but is ineffective when given 24 hr. beforehand.
Although the evidence strongly suggests that it is the ability of SKF 525-A to
inhibit microsomal detoxification of DMBA which is responsible for the potentia-
tion of tumour induction, this hypothesis requires further substantiation.
Despite the ability of 3-MC or SKF 525-A pretreatments at 24 hr. and 1 lhr.
respectively to prevent the rapidly lethal action of an intravenous injection with
15-0 mg. DMBA in rats, mammary tumour induction from this dose of carcinogen
was poorer than in control rats given 5 mg. DMBA or SKF 525-A-pretreated rats
given 2-5 mg. or 5-0 mg. DMBA. As previously reported (Badger et al., 1940;
Wheatley and Inglis, 1968), optimal dose levels for tumour induction probably
exist above which the carcinogenic action is less.
The results of 3-MC and SKF 525-A-pretreatments, taken together, suggest
that DMBA, per se, is responsible for mammary tumour induction and not a
metabolite produced in the liver, a conclusion previously reached (Kernohan.
Inglis and Wheatley, 1967). However, this does not preclude the possibility
that DMBA is metabolized to a carcinogenic compound within the mammary
epithelium itself.
Some compounds, unlike DMBA, appear to be metabolized by the liver before
exerting a carcinogenic action, e.g. 2-acetylaminofluorene undergoes N-hydroxy-
lation to its proximate carcinogenic form (see Miller and Miller, 1966). SKF
525-A may reduce the carcinogenicity of such compounds by inhibiting their
conversion to active metabolites, in contrast to its promoting action on tumour
induction by DMBA.
SUMMARY
Female Sprague-Dawley rats were treated with 1 mg. 3-methylcholanthrene
(3-MC) 24 hr. before intravenous injection of 2-5 or 5*0 mg. DMBA. By stimula-
ting metabolism of polycyclic hydrocarbons in this way, mammary tumour induc-
tion was prevented (2.5 mg. IDMBA) or reduced (5 0 mg. DMBA). In contrast.
pretreatment of rats with the potent inhibitor of drug-metabolism SKF 525-A
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at 10 mg./kg. intraperitoneally 1 hr. before DMBA led to an increase in mammary
tumour induction.
In rats given 3-MC 1 hr. before DMBA (an interval too short for stimulation
of lhepatic metabolism of DMBA to have occurred), and in rats given SKF 525-A
24 hr. before DMBA (by which time its inhibitory action on drug-metabolism
had worn off), mammary tumour induction was unaffected.
The results indicate that stimulation of the metabolism of DMBA increases
the rate of removal of the carcinogen as inactive derivatives whereas inhibition
of the metabolism allows the carcinogen to persist for longer in an active form,
thereby increasing tuimour induction. On this basis, DMBA appears responsible
for mammary tumour induction and not a metabolite produced in the liver,
although the possibility remains that the polycyclic hydrocarbon is metabolized
to its active form in the mammary epithelium.
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